News: carlos arteaga

Next Page »

Patient Lauded for Clinical Trial Participation

Wednesday, June 13th, 2012

A breast cancer patient who has enrolled in two clinical research trials at Vanderbilt-Ingram Cancer Center was the only presenter to receive a standing ovation during a recent Stand Up To Cancer (SU2C) news briefing at the American Association for Cancer Research (AACR) annual meeting in Chicago. Jeanette Daniel, 51, a metastatic breast cancer patient, […]

New Breast Cancer Gene Expression Identified

Monday, June 11th, 2012

A study led by Vanderbilt-Ingram Cancer Center investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn’t effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer. The study by lead author Justin Balko, Pharm.D., Ph.D., was published online June 10, 2012 […]

Postdoctoral Fellow of the Year

Wednesday, June 6th, 2012

Justin Balko, Pharm.D., Ph.D., was named Vanderbilt-Ingram Cancer Center’s Postdoctoral Fellow of the Year. He describes some of his breast cancer research pertaining to drug resistance and targeted therapeutics. He also notes the exceptional translational research environment that Vanderbilt provides. Balko is a researcher in the Carlos Arteaga lab.

Pink Out! Game to Tip Off Jan. 29

Friday, January 27th, 2012

Pink will be the color of the day during the Vanderbilt Commodore Women’s Basketball Team Pink Out! event to raise awareness for breast cancer research Sunday, Jan. 29, at 2 p.m. The Commodores will wear pink uniforms in their matchup in Memorial Gymnasium against the LSU Tigers. Fans are also invited to wear pink, the […]

Cohen’s Nobel-Winning Work Stands Test of Time

Thursday, December 8th, 2011

Twenty-five years ago on Dec. 10, King Carl XVI Gustaf of Sweden presented the Nobel Prize to Vanderbilt biochemist Stanley Cohen, Ph.D., for his discovery and characterization of epidermal growth factor (EGF) and its receptor. At the time, the implications of Cohen’s discovery two decades earlier had barely begun to be realized. Today the EGF […]

Breast Cancer Survivor Continues Her Fight

Monday, October 10th, 2011

As a 15-year breast cancer survivor, Lynne Cargen continues her fight against cancer as a research advocate at Vanderbilt-Ingram Cancer Center. She works with Carlos Arteaga, M.D. and his team of researchers in the Specialized Program of Research Excellence (SPORE) in Breast Cancer. Cargen said that she has been committed to raising awareness and becoming […]

Arteaga Earns Komen Award

Friday, October 7th, 2011

Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named one of the winners of this year’s Susan G. Komen for the Cure Brinker Awards for Scientific Distinction. The Brinker Awards for Scientific Distinction were established in 1992 to recognize the efforts of […]

Breast Cancer and Personalized Medicine

Wednesday, October 5th, 2011

Dr. Carlos Arteaga, director of the Vanderbilt-Ingram Cancer Center’s breast cancer program, describes how advances in personalized cancer medicine contributes to breast cancer treatment.

Breast Cancer Added to Gene Test Arsenal

Friday, July 8th, 2011

Breast cancer patients at Vanderbilt-Ingram Cancer Center can now have their tumor tissue tested for gene mutations that are important for treatment decisions. Information from genetic tests in the tumors will be used to match patients to the best cancer therapies available, including drugs that are in early clinical trial testing. Tumor mutation testing for […]

Breast Cancer Study Combines Therapies

Friday, March 18th, 2011

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The findings, reported in two papers in the Proceedings of the National Academy of Sciences (PNAS), suggest that upregulation of the HER3 receptor limits the effectiveness of two classes […]